Notable Labs, Ltd. (NTBL)
- Previous Close
0.9676 - Open
0.9800 - Bid 0.9167 x 100
- Ask 1.0400 x 100
- Day's Range
0.9501 - 1.0700 - 52 Week Range
0.8330 - 11.2000 - Volume
140,970 - Avg. Volume
85,284 - Market Cap (intraday)
8.703M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.4100 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.00
Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells.; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.
www.notablelabs.comRecent News: NTBL
Performance Overview: NTBL
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NTBL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NTBL
Valuation Measures
Market Cap
8.70M
Enterprise Value
-1.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.28
Price/Book (mrq)
0.58
Enterprise Value/Revenue
-3.46
Enterprise Value/EBITDA
0.07
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-73.13%
Return on Equity (ttm)
-166.90%
Revenue (ttm)
310k
Net Income Avi to Common (ttm)
-11.26M
Diluted EPS (ttm)
-3.4100
Balance Sheet and Cash Flow
Total Cash (mrq)
11.82M
Total Debt/Equity (mrq)
14.63%
Levered Free Cash Flow (ttm)
-10.06M